Evidence map›Paper›PMID 26546586›Full record

ArticleAnnals of the rheumatic diseases2016

Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.

Theresa Wampler Muskardin, Priyanka Vashisht, Jessica M Dorschner, Mark A Jensen, Beverly S Chrabot, Marlena Kern, Jeffrey R Curtis, Maria I Danila, Stacey S Cofield, Nancy Shadick and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. A20: a master regulator of arthritis.Arthritis research & therapy · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 11 institutions in 1 country.

Theresa Wampler MuskardinDivision of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Priyanka VashishtDivision of Rheumatology, University of Nebraska Medical Center, Omaha, USA.
Jessica M DorschnerDivision of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Mark A JensenDivision of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Beverly S ChrabotGwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA.
Marlena KernCenter for Genomics and Human Genetics, Feinstein Institute Medical Research, North Shore LIJ Health System, New York, New York, USA.
Jeffrey R CurtisDivision of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama, USA.
Maria I DanilaDivision of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama, USA.
Stacey S CofieldDivision of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama, USA.
Nancy ShadickDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Peter A NigrovicDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
E William St ClairDivision of Rheumatology and Immunology, Duke University, Durham, USA.
Clifton O BinghamDivisions of Rheumatology and Allergy, Johns Hopkins University, Baltimore, USA.
Richard FurieDivision of Rheumatology and Allergy-Clinical Immunology, North Shore-LIJ Health System, Lake success, New York, USA.
William RobinsonDivision of Immunology and Rheumatology, Stanford University, Stanford, California, USA.
Mark GenoveseDivision of Immunology and Rheumatology, Stanford University, Stanford, California, USA.
Christopher C StriebichDivision of Rheumatology, University of Colorado Denver, Denver, USA.
James R O'DellDivision of Rheumatology, University of Nebraska Medical Center, Omaha, USA.
Geoffrey M ThieleDivision of Rheumatology, University of Nebraska Medical Center, Omaha, USA.
Larry W MorelandDivision of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Marc LevesqueDivision of Rheumatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
S Louis BridgesDivision of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, Alabama, USA.
Peter K GregersenCenter for Genomics and Human Genetics, Feinstein Institute Medical Research, North Shore LIJ Health System, New York, New York, USA.
Timothy B NiewoldDivision of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-3532-6660
Mayo Clinic · USUniversity of Alabama at Birmingham · USNorthwell Health · USUniversity of Nebraska Medical Center · USBrigham and Women's Hospital · USStanford University · USUniversity of Pittsburgh · USDuke University · USJohns Hopkins University · USUniversity of Chicago · USUniversity of Colorado Denver · US

Funding

Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
Phenotype-Specific Immune Responses in the Systemic VasculitidesP30AR053503 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI SOLOSKI, MARK J · 2006 to 2015
$6.4M
Interferon Regulatory Factor 5 in Human Lupus PathogenesisR01AR065964 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NIEWOLD, TIMOTHY B · 2015 to 2018
$2.0M
Interferon Alpha as a Tool for Gene Discovery in Human LupusR01AR060861 · NIAMS · UNIVERSITY OF CHICAGO · PI NIEWOLD, TIMOTHY B · 2011 to 2015
$1.8M
The Role of IL-17 Axis in Inflammatory MyositisR01AR057781 · NIAMS · MAYO CLINIC ROCHESTER · PI NIEWOLD, TIMOTHY B, PETERSON, ERIK J · 2010 to 2014
$1.6M
Genetic Architecture of Rheumatoid Arthritis in African-AmericansK23AR062100 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DANILA, MARIA IOANA · 2012 to 2016
$674k
NCATS NIH HHS UL1 TR000430NIAID NIH HHS L30 AI071651NIAMS NIH HHS K23 AR062100NIAMS NIH HHS P30 AR053503NIAMS NIH HHS R01 AR057781NIAMS NIH HHS R01 AR060861NIAMS NIH HHS R01 AR065964
6 · The paper itself

Abstract

objectiveStudies suggest that circulating type I interferon (IFN) may predict response to biological agents in rheumatoid arthritis (RA). Prediction of response prior to initiating therapy would represent a major advancement.

methodsWe studied sera from a test set of 32 patients with RA from the Auto-immune Biomarkers Collaborative Network Consortium and a validation set of 92 patients with RA from the Treatment Efficacy and Toxicity in Rheumatoid Arthritis Database and Repository registry. The test set included those with good response or no response to tumour necrosis factor (TNF) inhibitors at 14 weeks by European League Against Rheumatism criteria. The validation set included subjects with good, moderate or no response at 12 weeks. Total serum type I IFN activity, IFN-α and IFN-β activity were measured using a functional reporter cell assay.

resultsIn the test set, an increased ratio of IFN-β to IFN-α (IFN-β/α activity ratio) in pretreatment serum associated with lack of response to TNF inhibition (p=0.013). Anti-cyclic citrullinated peptide antibody titre and class of TNF inhibitor did not influence this relationship. A receiver-operator curve supported a ratio of 1.3 as the optimal cut-off. In the validation set, subjects with an IFN-β/α activity ratio >1.3 were significantly more likely to have non-response than good response (OR=6.67, p=0.018). The test had 77% specificity and 45% sensitivity for prediction of non-response compared with moderate or good response. Meta-analysis of test and validation sets confirmed strong predictive capacity of IFN-β/α activity ratio (p=0.005).

conclusionsIncreased pretreatment serum IFN-β/α ratio strongly associated with non-response to TNF inhibition. This study supports further investigation of serum type I IFN in predicting outcome of TNF inhibition in RA.

Indexed as

AdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidBiomarkersDatabases, FactualFemaleHumansInterferon-alphaInterferon-betaMaleMiddle AgedPredictive Value of TestsPrognosisRegistriesAntirheumatic AgentsBiomarkersInterferon-alphaInterferon-betaTNF protein, humanTumor Necrosis Factor-alphaCytokinesRheumatoid ArthritisTNF-alphaTreatment

Identifiers

PMID26546586
PMCPMC4860184
OpenAlexW2229182764

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.